EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Cuproplasia and cuproptosis, two sides of the coin

Kaizhong Lu iD, Chandra Sugiarto Wijaya, Qinghua Yao, Hongchuan Jin, Lifeng Feng iD

Cancer Communications · 2025-05 · 45 (5) · 505-524

DOI: 10.1002/cac2.70001 ↗

At a glance

Übersichtsarbeit in Cancer Communications, published online on 2025-01-25. Written by Kaizhong Lu and 4 co-authors. Institution: Department of Medical Oncology, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Cancer Center of Zhejiang…. Major MEDLINE topics: Copper, Neoplasms. Cited 52 times so far (Crossref); 148 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Science Foundation of Zhejiang Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Copper is an essential micronutrient in the human body, mainly acting as a crucial cofactor required for a wide range of physiological processes across nearly all cell types. Recent advances revealed that tumor cells seize copper to fulfill their rapid proliferation, metastasis, immune evasion, and so on by reprogramming the copper regulatory network, defined as cuproplasia. Thus, targeting copper chelation to reduce copper levels has been considered a rational tumor therapy strategy. However, overloaded copper ions could be toxic, which leads to the aggregation of lipoylated mitochondrial proteins and the depletion of iron‐sulfur clusters, ultimately resulting in cell death, termed cuproptosis. Upon its discovery, cuproptosis has attracted great interest from oncologists, and targeting cuproptosis by copper ionophores exhibits as a potential anti‐tumor therapy. In this review, we present the underlying mechanisms involved in cuproplasia and cuproptosis. Additionally, we sum up the chemicals targeting either cuproplasia or cuproptosis for cancer therapy. Further attention should be paid to distinguishing cancer patients who are suitable for targeting cuproplasia or cuproptosis.

Subjects

MeSH terms (MEDLINE)

CopperNeoplasmsHumansAnimalsMitochondria

Author keywords

copper homeostasiscuproplasiacuproptosistherapeutics targeting coppertumor

Substances

Copper

Authors and institutions

  • Department of Medical Oncology, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang U…
  • Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, Zhejiang, P. R. China.
  • Key Laboratory for Research on the Pathogenesis of Inflammation-Cancer Transformation in Intestinal Diseases, Zhejiang Engineering Research Center of Intelligent Equipment of Chronic Chinese and Western Medicine, Hangzh…

ORCID profiles: Kaizhong Lu, Lifeng Feng

Funding

  • Natural Science Foundation of Zhejiang Province

Cite

APA

Lu, K., Wijaya, C. S., Yao, Q., Jin, H., & Feng, L. (2025). Cuproplasia and cuproptosis, two sides of the coin. Cancer Communications, 45(5), 505-524. https://doi.org/10.1002/cac2.70001

Vancouver

Lu K, Wijaya CS, Yao Q, Jin H, Feng L. Cuproplasia and cuproptosis, two sides of the coin. Cancer Communications. 2025;45(5):505-524. doi:10.1002/cac2.70001

BibTeX
@article{Lu2025,
  author = {Lu, Kaizhong and Wijaya, Chandra Sugiarto and Yao, Qinghua and Jin, Hongchuan and Feng, Lifeng},
  title = {Cuproplasia and cuproptosis, two sides of the coin},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {5},
  pages = {505--524},
  doi = {10.1002/cac2.70001}
}
Start for free →